4 melanoma patients

Aiming at finding possible reasons for the discrepancies between our findings and published data could be the amount of ONTAK used in patients, we filed an amendment to the clinical trial allowing the inclusion of additional 4 patients. These patients will receive higher doses (12microg/kg 3x and 18microg/kg 1x) before vaccination. Taking into account direct effects of ONTAK on DC, patients will be vaccinated some days after last ONTAK treatment (as soon as blood DC have recovered to 50% of pre ONTAK amount).

Third stage of DERMA-ER-DC 05 clinical trial.

• molecule type
• ONTAK

• cell type
• dendritic cell

created over 15 years ago (16 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]